Cleared Traditional

K252978 - ScioCardio ECG Analysis Platform

K252978 is an FDA 510(k) clearance for ScioCardio ECG Analysis Platform, manufactured by Synergen Technology Labs, LLC. The device is a Class 2 Cardiovascular device with product code DQK cleared through the Traditional 510(k) pathway after a 295-day FDA review.

K252978 · Synergen Technology Labs, LLC · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2026
Decision
295d
Days
Class 2
Risk

K252978 is an FDA 510(k) clearance for the ScioCardio ECG Analysis Platform. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Synergen Technology Labs, LLC (Dallas, US). The FDA issued a Cleared decision on July 9, 2026 after a review of 295 days - an extended review cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Synergen Technology Labs, LLC devices

FDA 510(k) Submission Details - K252978

510(k) Number K252978 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 17, 2025
Decision Date July 09, 2026
Days to Decision 295 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
170d slower than avg
Panel avg: 125d · This submission: 295d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DQK Device Classification - Class 2, Special Controls

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 271
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K252978.
EnSite™ X EP System
K262006 · Abbott Medical · Jul 2026
ZEUS Platform (FG0501US)
K252859 · iRhythm Technologies, Inc. · May 2026
EnSite™ X EP System
K260212 · Abbott Medical · Apr 2026
ACORYS MAPPING SYSTEM
K253861 · Corify Care S.L · Apr 2026
Synchrony
K253473 · Stereotaxis, Inc. · Apr 2026
HemoSphere Nano Monitor (HSNANO1)
K253186 · Edwards Lifesciences, LLC · Feb 2026